Modulation of stimulatory and non-stimulatory myeloid cells
AssigneeThe Regents of the University of California
InventorsMatthew Krummel, Miranda Broz, Denise Wolf, Joshua Pollack, Mikhail Biennewies
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein such as an antibody or antigen binding fragment thereof.
Claims24
1-88. (canceled)
A method of killing, disabling, or depleting non-stimulatory myeloid cells present in a cancer tissue of a subject in need thereof, comprising
- contacting the non-stimulatory myeloid cells with an antibody or antigen-binding fragment thereof that binds to the extracellular domain of a target protein expressed on the non-stimulatory myeloid cells selected from the group consisting of TREM2, LILRB4, MS4A7, C5AR1, LYVE1, ABCC3, MRC1/CD206, SIGLEC1, STAB1, TMEM37, MERTK, and TMEM119;
- wherein the antibody or antigen-binding fragment thereof is present in an amount effective to kill, disable, or deplete the non-stimulatory myeloid cells in the cancer tissue of the subject.
A method of treating a cancer in a subject in need thereof, comprising
- administering an antibody or antigen-binding fragment thereof that binds to the extracellular domain of a target protein expressed on one or more non-stimulatory myeloid cells selected from the group consisting of TREM2, LILRB4, MS4A7, C5AR1, LYVE1, ABCC3, MRC1/CD206, SIGLEC1, STAB1, TMEM37, MERTK, and TMEM119,
- wherein the non-stimulatory myeloid cells are present in the cancer and the antibody or antigen-binding fragment thereof is present in an amount effective to kill, disable, or deplete the non-stimulatory myeloid cells.
Dependencies are inferred from the claim text.